Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...

A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of a ...

Most organizations can afford a 10% efficiency cut, providing immediate financial relief, but how these cuts are done often ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

Opioid victims are not getting a "fair shake" in potential $7.4 billion settlement, a claimant in the Purdue Pharmacy ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to ...